<p>Part I : Old and new FcRs </p><p> </p><p>Hiromi Kubagawa, Yoshiki Kubagawa, Dewitt Jones, Tahseen H. Nasti, Mark Walter, and Kazuhito Honjo</p><p>The Old but New IgM Fc Receptor (FcμR)</p><p> </p><p>F.J. Li, W.J. Won, E.J. Becker Jr., J.L. Easlick, E. Tabengwa, R. Li, M. Shakhmatov, P.D. Burrows, and R.S. Davis</p><p>Emerging Roles for FCRL Family Members in Lymphocyte Biology and Disease</p><p> </p><p>Leo C. James</p><p>Intracellular antibody immunity and the cytosolic Fc receptor TRIM21</p><p> </p><p> </p><p>Part II: FcR signaling</p><p> </p><p>Anna Niarakis, Yacine Bounab, Luca Grieco, Roman Roncagalli, Jérôme Garin, Bernard Malissen, Marc Daëron, Denis Thieffry</p><p>Computational modeling of the main signaling pathways involved in mast cell activation</p><p> </p><p>Tarik Attout, Andres Floto and Pierre Launay</p><p>Calcium channels in FcR signaling</p><p> </p><p>Marcel Kuhny, Carolin N. Zorn, and Michael Huber</p><p>Regulation of FcεRI signaling by lipid phosphatases</p><p> </p><p> </p><p>Part III: FcR biology</p><p> </p><p>Marc Daëron</p><p>Fc Receptors as Adaptive Immunoreceptors</p><p> </p><p>Jerrard M Hayes, Eoin FJ Cosgrave, Weston B Struwe, Mark Wormald, Gavin P. Davey, Roy Jefferis, Pauline M Rudd</p><p>Glycosylation and Fc Receptors<sup></sup></p><p> </p><p>Birgitta Heyman</p><p>Antibodies as natural adjuvants</p><p> </p><p>Sanae Ben Mkaddem, Ivy Christou, Elisabetta Rossato, Laureline Berthelot, Agnès Lehuen and Renato C. Monteiro</p><p>IgA, IgA receptors and their anti-inflammatory properties</p><p> </p><p>Stylianos Bournazos, David J. DiLillo and Jeffrey V. Ravetch</p><p>Humanized mice to study FcγR function</p><p> </p><p>Dilip K. Challa, Ramraj Velmurugan, Raimund J. Ober and E. Sally Ward</p><p>FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions.</p><p> </p><p> </p><p>Part IV: FcRs and disease</p><p> </p><p>Xinrui Li, Andrew W Gibson and Robert P Kimberly</p><p>Human FcR polymorphism and disease.</p><p> </p><p>Hanane el Bannoudi, Andreea Ioan-Facsinay and René E. M. Toes</p><p>Bridging auto-antibodies and arthritis; the role of Fc Receptors</p><p> </p><p>P. Mark Hogarth, Jessica C. Anania, Bruce D. Wines</p><p>The FcγR of humans and non-human primates and their interaction with IgG: Implications for induction of inflammation, resistance to infection and the use of therapeutic monoclonal antibodies</p><p> </p><p> </p><p>Part V: FcRs and therapeutic antibodies</p><p> </p><p>Ann L White, Stephen A Beers and Mark S. Cragg</p><p>FcgRIIB as a key determinant of agonistic antibody efficacy </p><p> </p><p>Jantine E. Bakema and Marjolein van Egmond</p><p>Fc receptor dependent mechanisms of monoclonal antibody therapy of cancer; professionals at work</p><p> </p><p>Sybille Böhm, Daniela Kao and Falk Nimmerjahn</p><p>Sweet and Sour: The role of glycosylation for the anti-inflammatory activity of immunoglobulin G</p>
